Zimmer Partners LP Buys Shares of 202,500 Sana Biotechnology, Inc. (NASDAQ:SANA)

Zimmer Partners LP purchased a new position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 202,500 shares of the company’s stock, valued at approximately $2,025,000. Zimmer Partners LP owned about 0.09% of Sana Biotechnology as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. New York State Common Retirement Fund grew its position in Sana Biotechnology by 5.4% during the fourth quarter. New York State Common Retirement Fund now owns 40,564 shares of the company’s stock worth $166,000 after buying an additional 2,082 shares in the last quarter. Arizona State Retirement System grew its holdings in shares of Sana Biotechnology by 12.2% during the 4th quarter. Arizona State Retirement System now owns 27,527 shares of the company’s stock worth $112,000 after purchasing an additional 2,991 shares in the last quarter. ProShare Advisors LLC increased its position in shares of Sana Biotechnology by 14.8% during the first quarter. ProShare Advisors LLC now owns 32,690 shares of the company’s stock valued at $327,000 after purchasing an additional 4,210 shares during the period. Simplex Trading LLC increased its position in shares of Sana Biotechnology by 31.3% during the fourth quarter. Simplex Trading LLC now owns 18,080 shares of the company’s stock valued at $73,000 after purchasing an additional 4,313 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Sana Biotechnology by 42.1% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,257 shares of the company’s stock valued at $66,000 after purchasing an additional 4,815 shares in the last quarter. 88.23% of the stock is owned by institutional investors.

Sana Biotechnology Price Performance

Shares of NASDAQ:SANA traded down $0.73 during trading on Thursday, reaching $5.36. The stock had a trading volume of 1,729,153 shares, compared to its average volume of 2,514,811. The stock has a market capitalization of $1.19 billion, a PE ratio of -3.54 and a beta of 1.45. Sana Biotechnology, Inc. has a 52 week low of $2.74 and a 52 week high of $12.00. The business’s 50-day moving average price is $6.30 and its 200 day moving average price is $7.57.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.02). Analysts forecast that Sana Biotechnology, Inc. will post -1.15 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on SANA shares. Rodman & Renshaw assumed coverage on Sana Biotechnology in a research note on Wednesday, June 26th. They issued a “buy” rating and a $16.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Sana Biotechnology in a research report on Thursday, May 9th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Sana Biotechnology presently has a consensus rating of “Moderate Buy” and an average target price of $12.75.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.